Several brokerages have updated their recommendations and price targets on shares of Axsome Therapeutics (NASDAQ: AXSM) in the last few weeks:
- 10/14/2026 – Axsome Therapeutics had its “outperform” rating reaffirmed by Royal Bank Of Canada.
- 10/8/2026 – Axsome Therapeutics had its price target lowered by Royal Bank Of Canada from $297.00 to $295.00. They now have an “outperform” rating on the stock.
- 9/29/2026 – Axsome Therapeutics had its price target lowered by Deutsche Bank Aktiengesellschaft from $280.00 to $267.00. They now have a “buy” rating on the stock.
- 9/25/2026 – Axsome Therapeutics had its price target lowered by Morgan Stanley from $251.00 to $247.00. They now have an “equal weight” rating on the stock.
- 9/25/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
- 9/23/2026 – Axsome Therapeutics had its price target raised by Truist Financial Corporation from $200.00 to $285.00. They now have a “buy” rating on the stock.
- 9/18/2026 – Axsome Therapeutics had its “overweight” rating reaffirmed by Piper Sandler. They now have a $258.00 price target on the stock.
- 8/31/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $290.00 price target on the stock.
- 8/24/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
- 8/24/2026 – Axsome Therapeutics had its “buy” rating reaffirmed by UBS Group AG.
- 8/18/2026 – Axsome Therapeutics was upgraded by Zacks Research from “strong sell” to “hold”.
Insider Buying and Selling at Axsome Therapeutics
In related news, COO Mark L. Jacobson sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $208.65, for a total value of $2,086,500.00. Following the sale, the chief operating officer directly owned 10,000 shares in the company, valued at $2,086,500. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Herriot Tabuteau sold 45,004 shares of the firm’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $212.01, for a total value of $9,541,298.04. Following the transaction, the chief executive officer directly owned 7,229 shares in the company, valued at $1,532,620.29. This trade represents a 86.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 59,664 shares of company stock valued at $12,624,805. Corporate insiders own 20.60% of the company’s stock.
Axsome’s lead commercial product is Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride), an oral medicine approved in the United States for the treatment of major depressive disorder in adults.
Read More
- Five stocks we like better than Axsome Therapeutics
- Venezuela’s Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit
- PepsiCo’s Earnings Beat Masks a Bigger Problem With Its North American Business
- Tax Credit Turmoil: Why Enphase and SolarEdge Face a Tough Road
- A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
Receive News & Ratings for Axsome Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
